ADMA: a specific biomarker for pathologic progress in diabetic microvascular complications?. (April 2016)

• Record Type: Journal Article
• Authors: Jing, Zhiqiang; Kuang, Liqing; Wang, Yanping; He, Jiajia; Sun, Zilin; Liu, Naifeng; Yang, Jin
• Is Part Of: Biomarkers in medicine. Volume 10:Number 4(2016)
• Page Start: 385
• Page End: 395
• Publication Date: 2016-04
• Subjects: ADMA -- biomarker -- CML -- HbA1c -- microvascular complications; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2015-0007
• Languages: English
• ISSNs: 1752-0363

Abstract

Background: This study highlights the role of glycated hemoglobin (HbA1c), asymmetric demethylargine (ADMA) and N -ϵ-(carboxymethyl)-lysine (CML) in different periods of progress in Type 2 diabetes, and identifies a pathomechanism-based biomarker that is linked not only to the metabolic progresses but also to the underlying angiopathic progresses.Methods: Peripheral blood samples from 100 healthy volunteers, 227 subjects with prediabetes, 173 subjects with Type 2 diabetes and 92 subjects with early diabetic microvascular complications were collected and analyzed for HbA1c, ADMA and CML.Results: Compared to HbA1c and CML, ADMA is the strongest independent predictor and a significantly discriminative receiver operating characteristics profile, clearly distinguishing those with early diabetic microvascular complications.Conclusions: ADMA maybe serve as a pathomechanism-based biomarker, predicting the progression of microvascular complications.